April 7, 2025 7:50am

“In financial markets, a "dead cat bounce" is a temporary, short-lived recovery in a declining market or asset price ....”  However, after tariff pounding on Friday; how close to the bottom for buys because … “at some point, we will get a tradable rally”

Pre-open Indications: 6 Negative Indications

News: Beam Therapeutics (BEAM +$0.33 pre-open) presented additional data from the P1/2 clinical trial of BEAM-302 in patients with alpha-1 antitrypsin deficiency (AATD). Positive initial safety and efficacy data from the P1/2 trial of BEAM-302 were previously reported in March 2025. Preliminary results from the 1st 3 single-ascending dose cohorts demonstrated that BEAM-302 was well tolerated, with single doses of BEAM-302 leading to durable dose-dependent correction of the disease-causing mutation and total AAT protein levels above the therapeutic threshold in the 60 mg dose cohort.

I was once told by a “very” prominent figure early in my career, “write it right, keep it tight without hype and never lose the stride to guide the reader - me” – pretty simple instructions to follow

No false narratives or fake news; to read insights and analysis on the latest sector action, check out Pre-Open Brief 

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened to make “it” happen today!

 

Friday’s night’s … RegMed Investors (RMi) Closing Bell: another fall to newer bottoms… https://www.regmedinvestors.com/articles/13868

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB: HRGN), The chokehold got tighter cutting-off any capacity to lift multiple going concern at-risk marker … https://www.regmedinvestors.com/articles/13812

 

Monday; the pre-open Dow futures are DOWN -2.13% or (-819 points), the S&P futures DOWN -2.29% or (-117 points) and the Nasdaq futures are DOWN -2.63% or (-460 points)

  • U.S. stock futures were lessoned while hit once again on Monday, 4/7
  • European stocks dropped -4% mid-day,
  • Asia-Pacific markets extended their sell-off, Hand Seng -13.22 and the mainland CSI -7.05%

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

Friday: The Dow closed DOWN -2,231.07 points or -5.50%, the S&P closed DOWN -322.44 points or -5.97% while the Nasdaq closed DOWN -962.82 points or -5.82%

Economic Data Docket: None

 

Q2- April – 3 negative and 1 positive closes

  • Q1/25 – March, 10 positive and 11 negative closes
  • February – 12 holiday, 11 negative and 7 positive closes
  • January - 2 holidays, 1 market close, 10 negative and 10 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.

A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

  • Better part of valor to not lead any investor to temptation; yet again, I am passing on forecasting the daily indications as to expectation while the aftermarket blanked while the pre-open waits for the …  econs, it is still a mix of ups, downs and just uncertainty

Although … “Some indications” according to the windsock ..

Negative Indications:

  • Alnylam Pharmaceuticals (ALNY) closed down -$26.42 after Thursday’s -$4.46, Wednesday’s +$11.07, Tuesday’s -$14.26 and Monday’s +$1.46 with a negative -6.74 or -2.86% pre-market
  • AxoGen (AXGN) closed down -$0.82 after Thursday’s -$0.65, Wednesday’s -$0.12, Tuesday’s -$0.69 and Monday’s +$0.15 with a negative -$0.30 or -1.85% pre-market
  • Ultragenyx Pharmaceuticals (RARE) closed down -$2.70 with a negative -$3.22 or -9.93% pre-market
  • CRISPR Therapeutics (CRSP) close down -$0.01 with a negative -$0.96 or -2.94% pre-market
  • Ionis Pharmaceuticals IONS) closed down -$1.43 with a $0.59 or -2.18% pre-market
  • Beam therapeutics (BEAM) closed down -$1.19 with a negative -$0.55 or -3.60% pre-market

 

The BOTTOM LINE:   Maintaining, “I think speculative behavior in this current market has ascended to a level beyond common sense.”

Merger and acquisition (M&A) activity; sector companies will seek opportunities to sell to better financed companies that can "deal with these additional costs associated of R&D and escalating SG&A.”

NOT much has changed, as I have written, “uncle algo and his trading dwarfs” determine the heights or lows of share pricing”

What could 2025 have in store for the capital access space as Partners are the gift of life!

  • "You'll see a number of cell and gene therapy comandantes drive for secondaries – they’re desperate for cash, but I do think a lot of cell and gene therapy sector companies NEED to be focused on what is driving their own growth —they're focused on a lot of change BUT … that's happening in the market… capital expansion is second.

I seem to be asking a question followed by a question …

  • Do we need to brace ourself for more economics and their down trending affect?
  • Is this market STILL “bubblicious” my concerns are macroeconomic and valuation

 Welcome to my world of defining the “grey’ in our universe!

  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.